Geron Management to Present at Two Key Investor Conferences in September
Event summary
- Geron management to participate in two investor conferences in September 2026.
- Fireside chat at Cantor Global Healthcare Conference on September 9, 2026, at 8:00 a.m. ET.
- Fireside chat at H.C. Wainwright Conference on September 15, 2026, at 3:30 p.m. ET.
- Live and archived audio webcasts available via Geron’s investor relations page.
The big picture
Geron’s participation in high-profile investor conferences comes as the company transitions from clinical-stage to commercial-stage, with RYTELO now approved in key markets. The presentations will be closely watched for updates on the myelofibrosis trial and commercialization strategy, particularly as the hematology space sees increasing competition and regulatory scrutiny. The events provide an opportunity for Geron to reinforce its position as a focused player in blood cancer therapeutics.
What we're watching
- Clinical Pipeline
- How progress in pivotal Phase 3 trial for myelofibrosis will be addressed.
- Commercial Strategy
- Whether Geron can sustain momentum for RYTELO in LR-MDS market.
- Investor Sentiment
- The pace at which management can reassure investors about execution risks.